Alps Advisors Inc Dynavax Technologies Corp Transaction History

Alps Advisors Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $19,242 - $22,020	-1,470 Reduced 5.88%	23,550 $329,000
Q3 2023 Nov 14, 2023	BUY	$12.64 - $14.99 $316,252 - $375,049	25,020 New	25,020 $369,000
Q4 2022 Feb 14, 2023	SELL	$10.27 - $13.29 $10 - $13	-1 Reduced -0.0%	28,218 $300,000
Q3 2022 Nov 14, 2022	SELL	$9.93 - $17.44 $49,868 - $87,583	-5,022 Reduced 15.11%	28,219 $295,000
Q2 2022 Aug 11, 2022	SELL	$7.45 - $12.83 $2,562 - $4,413	-344 Reduced 1.02%	33,241 $419,000
Q1 2022 May 16, 2022	BUY	$9.75 - $14.44 $327,453 - $484,967	33,585 New	33,585 $364,000
Q4 2018 Feb 04, 2019	SELL	$8.14 - $13.28 $901,968 - $1.47 Million	-110,807 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$11.85 - $16.0 $242,119 - $326,912	20,432 Added 22.61%	110,807 $1.37 Million
Q2 2018 Aug 02, 2018	BUY	$15.15 - $20.75 $351,904 - $481,981	23,228 Added 34.59%	90,375 $1.38 Million
Q2 2018 Jul 25, 2018	SELL	$15.15 - $20.75 $213,993 - $293,093	-14,125 Reduced 17.38%	67,147 $1.26 Million
Q1 2018 May 01, 2018	BUY	$14.65 - $19.9 $206,931 - $281,087	14,125 Added 21.04%	81,272 $1.61 Million
Q4 2017 Feb 05, 2018	BUY	$17.3 - $24.08 $1.16 Million - $1.62 Million	67,147	67,147 $1.26 Million

257

132M

371K

99.2K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.44B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.